UNSPSC 51292008: Diisopromine or disoprominum

This classification denotes a muscle relaxant with the molecular formula C21H29N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2825S6AW9U, chemically known as benzenepropanamine, n,n-bis(1-methylethyl)-.gamma.-phenyl- but generally known as diisopromine, which bears US NIH Compound Identifier 22262. European Medicines Agency schedules Diisopromine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07143MIG.

UNSPSC 51292008 Diisopromine or disoprominum is a Commodity code that nominally describes a specific chemical compound, but the recent state and local opportunities tagged to it reflect actual procurement for pharmaceutical products and health-system supplies rather than diisopromine specifically. State and local buying under this code centers on naloxone (opioid reversal agents), generic multi-source pharmaceuticals, over-the-counter products, and related drug-delivery or deactivation systems procured by county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Issuing bodies include county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local governments across multiple states including Oregon). The actual procurement activity shows a strong emphasis on supply-chain compliance, including cGMP certification, Drug Supply Chain Security Act adherence, NDC verification, and authorized-wholesaler relationships.

Recent opportunities span Florida, Texas, and the MMCAP footprint (Minnesota and Oregon). Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building and a response deadline of July 26, 2023 (note: the posting date of June 30, 2026 and response deadline of July 26, 2023 reflect a data inconsistency in the source). The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory procurement signaling future formal RFP activity. Minnesota's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and demonstrating the scale of multi-state cooperative procurement under this code.